EKEwa Kumiega

Ewa Kumiega

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ewa Kumiega has a total of 17 co-authors. Here are the top co-authors by number of shared publications:

  • Agnieszka Noszczyk-Nowak

    Department of Internal Medicine and Clinic of Diseases of Horses, Dogs and Cats, Faculty of Veterinary Medicine, Wrocław University of Environmental and Life Sciences, Wrocław, Poland

    1 shared publication
  • Agnieszka Noszczyk-Nowak

    Department of Internal Medicine and Clinic of Diseases of Horses, Dogs and Cats, Wrocław University of Environmental and Life Sciences, Grunwaldzki Sq. 47, 50-366 Wrocław, Poland

    1 shared publication
  • Agnieszka Zak

    Department of Immunology, Pathophysiology and Veterinary Preventive Medicine, Wrocław University of Environmental and Life Sciences, Poland

    1 shared publication
  • Anna Bogucka

    Vetlab, Polish Veterinary Laboratories , Wrocław , Poland

    1 shared publication
  • Artur Niedzwiedz

    Department of Internal Medicine and Clinic of Diseases of Horses, Dogs and Cats, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, 50-366 Wroclaw, Poland

    1 shared publication
  • Dorota Dlugopolska

    Department of Internal Medicine and Clinic of Diseases of Horses, Dogs and Cats, Faculty of Veterinary Medicine, Wroclaw University of Environmental and Life Sciences, 50-366 Wroclaw, Poland

    1 shared publication

Latest Publications

  • Open Access

    Pharmacokinetics of Sulfasalazine and the Temporal Profiles of Sulfapyridine and Its Metabolites Following Nasogastric Administration in Six Healthy Adult Horses

    by Miłosz Grabski, Olga Wachełko, Marcin Zawadzki, Paweł Szpot, Ewa Kumiega, Artur Niedźwiedź

    Sulfasalazine is an azo-linked prodrug of sulfapyridine and 5-aminosalicylic acid that is activated by bacterial azoreductases in the distal gut. Its disposition has not been described in horses, in which extensive hindgut fermentation may influence prodrug activation. This study characterised the concentration-time profile of sulfasalazine and the appearance of sulfapyridine, 5-hydroxy-sulfapyridine and N4-acetyl-sulfapyridine after a single oral dose. Six healthy adult Warmblood horses received sulfasalazine (16 mg/kg) by nasogastric tube, and blood was sampled hourly for 14 h. Sulfasalazine and sulfapyridine were quantified by liquid chromatography-tandem mass spectrometry; both metabolites were assessed semi-quantitatively as peak-area ratios. Sulfasalazine was measurable from 1 h and reached a median maximum concentration of 386.61 ng/mL (Q1–Q3 330.44–504.35) at a median of 5.5 h, then declined steeply. Sulfapyridine remained near the limit of detection for six hours, rose abruptly between 7 and 8 h and peaked at a median of 2794.00 ng/mL (2381.87–3146.14) at 9.0 h, approximately seven-fold above the parent-drug maximum. Both metabolites rose in parallel with sulfapyridine. This timing matches published equine orocaecal transit times, indicating that sulfasalazine reaches the hindgut largely intact and is activated there by microbial azoreduction. Systemic sulfapyridine exposure was substantial and should be considered in any therapeutic use.

  • Open Access

    Bacterial isolates and antimicrobial susceptibility patterns in tracheal wash samples from horses with equine asthma in Poland

    by Natalia Siwińska, Dorota Długopolska, Agnieszka Żak-Bochenek, Marzena Paszkowska, Paweł Rudzki, Ewa Kumiega, Anna Bogucka

    Introduction: Equine asthma (EA) is a chronic inflammatory lower-airway disease. Bacterial growth from tracheal wash (TW) may occur in samples from horses with EA, but may represent colonisation rather than active infection. This study described cultivable bacterial isolates recovered from TW samples from horses with EA in Poland and assessed their antimicrobial susceptibility patterns and association with month/season of sampling and airway neutrophil percentage. Material and Methods: In total, 165 adult horses diagnosed with EA according to American College of Veterinary Internal Medicine–based criteria underwent endoscopy, TW sampling with a double-guarded catheter and bronchoalveolar lavage fluid cytology. The samples were cultured conventionally and their bacterial content identified with MALDI-TOF MS; bacteria were tested for antimicrobial susceptibility. Associations between culture results and categorical variables were analysed using chi-squared/Fisher-type tests with Monte Carlo simulation where appropriate; effect size was reported as Cramer’s V. Results: Culture results were positive in 117/165 horses’ samples (70.9%), and bacteria were isolated from 116/165 (70.3%). The most frequently recovered bacteria were Streptococcus equi subsp. zooepidemicus , Pseudomonas aeruginosa and Klebsiella pneumoniae . Culture positivity was not associated with month or season of sampling, whereas analysis of bacterial genus by month suggested a modest association (χ 2 = 100.72, degrees of freedom = 77, P-value = 0.036; Cramer’s V = 0.305). No clear association was observed with airway neutrophil percentage. Antimicrobial susceptibility patterns varied by organism. Conclusion: Cultivable bacteria are frequently recovered from TW samples of horses with EA. Positive culture results should not be interpreted as evidence of bacterial infection without supporting clinical and cytological findings. Antimicrobial treatment, when clinically justified, should be guided by culture and susceptibility testing.

  • Open Access

    Iron parameters analysis in dogs with myxomatous mitral valve disease

    by Ewa Kumiega, Kamil A Kobak, Agnieszka Noszczyk-Nowak, Monika Kasztura

    Myxomatous mitral valve disease (MMVD) is the most common acquired cardiovascular disease in small breed dogs. In contrast to human patients with heart failure (HF), iron deficiency (ID) prevalence in dogs with MMVD is weakly known. The study aimed to assess the usability of ID markers in serum and reticulocyte parameters from whole blood of dogs with MMVD to evaluate early ID symptoms. Sixty-eight dogs (43 male and 25 female) were included in the study. MMVD dogs were assigned according to the 2019 ACVIM guidelines for groups B1 (n = 9), B2 (n = 10), C (n = 27) and D (n = 10). Groups were also combined into B1 and B2 as non-symptomatic HF and C with D as symptomatic HF. Healthy controls were 12 dogs. Serum iron concentration below the reference range in dogs with MMVD was 12.5%. Other ID indices, such as %SAT, UIBC, and TIBC were similar in the MMVD groups and healthy controls (p > 0.05 for all parameters). Statistical comparison between control group and 4 groups of different stages of MMVD showed that significant differences occur only in serum transferrin. The assessment of ferritin and soluble transferrin receptors using Western Blotting did not show differences between control (n = 7) and MMVD (n = 33) dogs. Study has shown positive correlation between ID parameters and echocardiographic indices such as LA/Ao and LVIDdN, and some biochemical parameters. A significant increase in reticulocytes percentage, assessed manually, was observed in the HF group of animals (p = 0.027) compared to the control group. Studies have shown that ID parameters in serum are not significantly different in dogs with MMVD compared to healthy dogs. However, there is a clear correlation between atrial size and normalised left ventricular size to body size and some biochemical parameters, including ID parameters and therefore the severity of MMVD.